Brief: ADC Therapeutics Doses First Patient In Phase 1B Clinical Trial Of Zynlonta In Combination With Other Anti-Cancer Agents
29/06/2022 12:44
June 29 (Reuters) - ADC Therapeutics SA ADCT.N :
* ADC THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1B CLINICAL
TRIAL
OF ZYNLONTA® (LONCASTUXIMAB TESIRINE-LPYL) IN COMBINATION WITH
OTHER ANTI-CANCER AGENTS
Source text for Eikon: ID:nBw62pskza
Further company coverage: ADCT.N
Recent news on ADC Therapeutics SA
See all newsADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics falls on higher rates of serious side-effects in cancer trial
Switzerland's ADC Therapeutics beats Q1 revenue estimates
Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million